Common Stock, Par Value $1.00
- Symbol
- JNJ
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Johnson & Johnson
JNJNYSEEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 27, 2026, the Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims.…
Press release in this filing
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation →Company context
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.
Current securities
Registered securities in this filing
Johnson & Johnson · 8-K · Filed 2026-07-28
1.150% Notes Due November 2028
- Symbol
- JNJ28
- Exchange
- NYSE
- Classification
- DEBT
2.700% Notes Due February 2029
- Symbol
- JNJ29B
- Exchange
- NYSE
- Classification
- DEBT
3.200% Notes Due June 2032
- Symbol
- JNJ32
- Exchange
- NYSE
- Classification
- DEBT
3.050% Notes Due February 2033
- Symbol
- JNJ33B
- Exchange
- NYSE
- Classification
- DEBT
1.650% Notes Due May 2035
- Symbol
- JNJ35
- Exchange
- NYSE
- Classification
- DEBT
3.350% Notes Due June 2036
- Symbol
- JNJ36A
- Exchange
- NYSE
- Classification
- DEBT
3.350% Notes Due February 2037
- Symbol
- JNJ37B
- Exchange
- NYSE
- Classification
- DEBT
3.550% Notes Due June 2044
- Symbol
- JNJ44
- Exchange
- NYSE
- Classification
- DEBT
3.600% Notes Due February 2045
- Symbol
- JNJ45
- Exchange
- NYSE
- Classification
- DEBT
3.700% Notes Due February 2055
- Symbol
- JNJ55
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On July 27, 2026, the Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims. The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028. The press release further discussing this announcement is attached below as Exhibit 99.1.